ProtoKinetix Inc.'s Commercialization Of AAGP(TM)

VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 21, 2005--ProtoKinetix, Inc.'s (OTCBB:PKTX) objective for 2005 was to bring their unique family of AAGP(TM) molecules to market in the areas of cell, tissue and organ preservation and protection. The Company has been able to successfully demonstrate that their proprietary molecules can effectively defend the vast array of human cell lines against oxidative stress ad ultraviolet radiation. In the world of biotechnology, prior to the introduction of AAGP(TM), there has been nothing that retards or fights the natural decay or aging of human cells as well as AAGP(TM).

Back to news